Andrew Komjathy has been appointed chief commercial officer of Catabasis Pharmaceuticals (NASDAQ: CATB). He joins the Cambridge, MA, drug developer from Alkermes (NASDAQ: ALKS), where he was vice president of commercial sales. His experience also includes positions at Genzyme, Shire, and Biogen (NASDAQ: BIIB). Catabasis has changed its therapeutic focus several times
, having pursued drugs for diabetes and high cholesterol among other diseases. Its most advanced compound, edasalonexent, is in Phase 3 testing in Duchenne muscular dystrophy.
Sponsored · Whitepaper
Acknowledging various stakeholder networks and regulatory environment variances is essential to uncover the right decision-makers in support of biologics or biosimilars
IBM Watson
Sponsored · Whitepaper
Create well-controlled, biologically relevant test systems and validate them to support FDA approvals
Absorption Systems
Sponsored · Video
A Fireside Chat with Fish & Richardson Principal Teresa Lavoie
Fish & Richardson
